6. Conclusions
In our preclinical study on DSS rats with hypertension, we observed that
the novel ARNi drug (S086) had a significant antihypertensive effect.
Its effect was superior to that of the first-generation ARNi drug
LCZ696. These results support further phase 2 and phase 3 clinical
studies on S086 to explore its efficacy and safety in treating patients
with hypertension.
Acknowledgments: We acknowledge all supporting staffs from the
Salubris and WuXi AppTec. The current work was supported by Shenzhen
Science and Technology Program (Grant No. KQTD20200820151701004).
Conflict of interest statement: S086 is Salubris’ developing
product, and Salubris is the patent owner.
Funding: Shenzhen Science
and Technology Program (Grant No. KQTD20200820151701004)